Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.

Abstract excerpt

In FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML), relapse after allogeneic hematopoietic cell transplantation (alloHCT) is the leading cause of treatment failure and mortality. We evaluated real-world adherence and persistence of FLT3-like-tyrosine kinase inhibitors as alloHCT maintenance in FLT3mut+ AML. Claims data were extracted from adults with AML with ≥1 alloHCT between January 2016 and June 2022 who...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to fms-Like Tyrosine Kinase 3